Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.

Pharmacogenetics and genomics - 1 May 2015

Foulds James A, Ton Kim, Kennedy Martin A, Adamson Simon J, Mulder Roger T, Sellman J Douglas

Abstract excerpt

A functional polymorphism rs1799971 (A118G) in the μ-opioid receptor gene (OPRM1) produces an amino acid substitution Asn40Asp, which is believed to influence naltrexone response in nondepressed alcohol-dependent patients. In this study, patients with alcohol dependence and major depression (n=108) received open-label naltrexone and clinical case management for 12 weeks, and were randomized to citalopram or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to OPRM1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Alcoholism

Share to Depressive Disorder, Major

Share to Naltrexone

Share to Polymorphism, Single Nucleotide

Share to Receptors, Opioid, mu

Source

Identifiers

PMID: 25715171
DOI: 10.1097/FPC.0000000000000128

Genes

OPRM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients.PMID 25715171Read ↗

Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.Semantic proximity Read ↗

OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption.Semantic proximity Read ↗

The μ-opioid receptor and treatment response to naltrexone.Semantic proximity Read ↗

Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype.Semantic proximity Read ↗

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.Semantic proximity Read ↗

Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.Semantic proximity Read ↗

Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers.Semantic proximity Read ↗

μ-Opioid receptor gene (OPRM1) polymorphism A118G: lack of association in Finnish populations with alcohol dependence or alcohol consumption.Semantic proximity Read ↗

Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder.Semantic proximity Read ↗

Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.